The Suicide Gene Diphtheria Toxin A Based Therapy in Cancer Treatment

키워드

참고문헌 (92)

1. Abdul-Ghani R, "Use of transcriptional regulatory sequences of telomerase for selective killing of cancer cells", Mol Ther, 2, pp.539~544 (2000)
2. Amit D, "Development of targeted therapy for bladder cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of H19 and IGF-P4 regulatory sequences", Journal of Translational Medicine, 8, pp.134~ (2010)
3. Amit D, "Development of targeted therapy for bladder cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of IGF2-P3 and IGF2-P4 regulatory sequences", Int J ClinExp Med, 4(2), pp.91~102 (2011)
4. Anderson DG, "Structure", property studies of polymeric gene delivery using a library of poly, 2005, pp.11, 426~434
5. Anderson GD, "A polymer library approach to suicide gene therapy for cancer", PNAS, pp.16028~16033 (2004)
6. Ariel I, "The imprinted H19 gene is a marker of early recurrence in human bladder carcinoma", Mol Pathol, 53, pp.320~323 (2000)
7. Ayesh B, "Inhibition of tumor growth by DT-A expressed under the control of IGF2 P3 and P4 promoter sequences", Mol Ther, 7, pp.535~541 (2003)
8. Ayesh B, "Inhibition of tumor growth by DT-A expressed under the control of IGF2 P3 and P4 promoter sequences", Molecular Therapy, 7, pp.4~ (2003)
9. 이옥희, "Egr-1 mediates transcriptional activation of IGF-II gene in response to hypoxia", CANCER RESEARCH, 59, pp.5989~5994 (1999), AMER ASSOC CANCER RESEARCH
10. Bingle L, "The putative ovarian tumour marker gene HE4 is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms", Oncogene, 21, pp.2768~2773 (2002)
11. Breidenbach M, "Mesothelin-mediated targeting of adenoviral vectors for ovarian cancer gene therapy", Gene Therapy, 12, pp.187~193 (2005)
12. Cao GW, "Gene therapy for human colorectal carcinoma using human CEA promoter controlled bacterial ADP-ribosylating toxin genes human CEA: PEA & DTA gene transfer", World J Gastroenterol, 4, pp.388~391 (1998)
13. Chiron MF, "Cleavage of pseudomonas exotoxin and diphtheria toxin by a furin-like enzyme prepared from beef liver", J Biol Chem, 269, pp.18167~18176 (1994)
14. Choe S, "The crystal structural of diphtheria toxin", Nature, 357, pp.216~222 (1992)
15. Clements JA, "The glandular kallikrein family of enzymes: Tissue-specific expression and hormonal regulation", Endocrinol Rev, 10, pp.393~419 (1989)
16. Collier RJ, "Diphtheria toxin: Mode of action and structure, bacteriological reviews", American Society for Microbiology, 39, pp.54~85 (1975)
17. Cooper MJ, , J Urol, 155, pp.2120~2127 (1996)
18. Deng Q, "Molecular mechanism of the cytotoxicity of ADP-ribosylating toxins", Annu Rev. Microbiol, 62, pp.271~288 (2008)
19. Dinh P, "New therapies for ovarian cancer: cytotoxics and molecularly targeted agents", Crit Rev Oncol Hematol, 67, pp.103~112 (2008)
20. Dixon CS, "The control of prostate-specific antigen expression and gene regulation by pharmacological agents", Pharmacol Rev, 53, pp.73~91 (2001)
21. Doherty A, "Correlation of the osteoblastic phenotype with prostate-specific antigen expression in metastatic prostate cancer: Implications for paracrine growth", J Pathol, 188, pp.278~281 (1999)
22. Dugimont T, , Mol. Cell, 85, pp.117~124 (1995)
23. Engstrom W, "Transcriptional regulation and biological significance of the insulin like growth factor II gene", Cell Prolif, 31, pp.173~189 (1998)
24. Fogar P, "Heat-induced transcription of diphtheria toxin A or its variants, CRM176 and CRM197: Implications for pancreatic cancer gene therapy", Gene Ther, 17, pp.58~68 (2010)
25. Gordon VL, "Crystal structure of the complex of diphtheria toxin with an extracellular fragment of its receptor", Molecular Cell, 1, pp.67~78 (1997)
26. Hahn H, "Patched target Igf2 is indispensable for the formation of medulloblastoma and rhabdomyosar-coma", J Biol Chem, 275, pp.28341~28344 (2000)
27. Hellstrom I, "SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and", or each other, 2008, pp.622, 15~21
28. Hellström I, "The He4 protein is a biomarker for ovarian carcinoma", Cancer Res, 63, pp.3695~3700 (2003)
29. Holthuizen P, "Identification and initial characterization of a fourth leader exon and promoter of the human IGF-II gene", Biochim Biophys Acta, 1087, pp.341~343 (1990)
30. Honjo T, "Adenosin diphosphate ribisylation of aminoacyl transferase II and inhibition of protein synthesis by diphtheria toxin", The Journal of Biological Chemistry, 246, pp.4251~4260 (1971)
31. Huang YH, "Nanoparticledelivered suicide gene therapy effectively reduces ovarian tumor burden in mice", Cancer Res, 69, pp.6184~6191 (2009)
32. Ilan Y, "Transient immuno-suppression with FK506 permits long-term expression of therapeutic genes introduced into the liver using recombinant adenoviruses in the rat", Hepatology, 26, pp.949~956 (1997)
33. Jia W, "Viral vectors for cancer gene therapy: viral dissemination and tumor targeting", Current Gene Therapy, 5, pp.133~142 (2005)
34. Joeng HC, "Toxin binding site of the diphtheria toxin receptor: loss and gain of diphtheria toxin binding of monkey and mouse herapinbinding, epidermal growth factor-like growth factor precursors by reciprocal site-directed mutagenesis", Molecular Microbiology, 29(5), pp.1275~1284 (1998)
35. Kaul P, "Roles of Glu 349 and Asp 352 in membrane insertion and translocation by diphtheria toxin", Protein Sci, 5, pp.6875~6692 (1996)
36. Kawamoto K, "Possible paracrine mechanism of insulin-like growth factor-2 in the development of liver metastases from colorectal carcinoma", Cancer, 85, pp.18~25 (1999)
37. Kondo M, "Frequent loss of imprinting of the H19 gene is often associated with its overexpression in human lung cancers", Oncogene, 10, pp.1193~1198 (1995)
38. Kunitomi M, "Selective inhibition of hepatoma cells using diphtheria toxin A under the control of the promoter", enhancer region of the human alpha-fetoprotein gene, 2000, pp.91, 343~350
39. Lambotte P, "Primary structure of diphtheria toxin fragment B: structural similarities with lipid-binding domains", The Journal of Cell Biology, 87, pp.837~840 (1980)
40. Latham JP, "Prostatespecific antigen promoter", enhancer driven gene therapy for prostate cancer: construction and testing of a tissuespecific adenovirus vector, 2000, pp.60, 334~341
41. Lee EJ, "Cell-specific cre-mediated activation of the diphtheria toxin gene in pituitary tumor cells: potential for cytotoxic gene therapy", Human Gene Ther, 13, pp.533~542 (2002)
42. Lee YI, "Activation of the insulin-like growth factor II transcription by afiatoxin B1 induced p53 mutant 249 is caused by activation of transcription complexes; implications for a gain-of-function during the formation of hepatocellular carcinoma", Oncogene, 19, pp.3717~3726 (2000)
43. Lemichez E, "Menbrane translocation of diphtheria toxin fragment A exploits early to late endosome trafficking machinery", MolMicrobiol, 23, pp.445~457 (1997)
44. Li Y, "Prostate-specific expression of the diphtheria toxin A chain : Studies of inducibility and specificity of expression of prostatespecific antigen promoter-driven DT-A Adenovira-mediated gene transfer", Cancer Res, 62, pp.2576~2582 (2002)
45. Lidor YJ, "In vitro expression of the diphtheria toxin A-chain gene under the control of human chorionic gonadotropin gene promoters as a means of directing toxicity to ovarian cancer cell lines", Am J Obstet Gynecol, 177, pp.579~585 (1997)
46. Lustig-Yariv O, "The expression of the imprinted genes H19 and IGF-2 in choriocarcinoma cell lines. Is H19 a tumor suppressor gene?", Oncogene, 15, pp.169~177 (1997)
47. Martin V, "Cancer gene therapy by thyroid hormone-mediated expression of toxin genes", Canc Res, 60, pp.3218~3224 (2000)
48. Maxwell F, "Regulated expression of a diphtheria toxin A-chain gene transfected into human cells: possible strategy for inducing cancer cell suicide", Cancer Res, 46, pp.4660~4664 (1986)
49. Maxwell F, "Cloning, sequence determination, and expression in transfected cells of the coding sequence for the tox 176 attenuated diphtheria toxin chain", MolCel Bio, 7, pp.1576~1579 (1987)
50. Maxwell IH, "Expression of the diphtheria toxin A-chain coding sequence under the control of promoters and enhancers from immunoglobulin genes as a means of directing toxicity to B-lymphoid cells", Canc Res, 51, pp.4299~4304 (1991)
51. Mineo R, "Promoter usage for insulin-like growth factor-II in cancerous and benign human breast, prostate, and bladder tissues, and confirmation of a 10th exon", Biochem Biophys Res Commun, 268(3), pp.886~892 (2000)
52. Mitamura T, "Structure-function analysis of the diphtheria toxin receptor toxin binding site by site-directed mutagenesis", The Journal of Biological Chemistry, 272, pp.27084~27090 (1997)
53. Mizrahi A, "Development of targeted therapy for ovarian cancer mediated by a plasmid expressing diphtheria toxin under the control of H19 regulatory sequences", Journal of Translational Medicine, 7, pp.69~ (2009)
54. Mizrahi A, "Treatment of ovarian cancer ascites by intraperitoneal injection of diphtheria toxin A chain-H19 vector: A case report", J Med Case Rep, 4, pp.228~ (2010)
55. Morimoto H, "Diphtheria toxin and Pseudomonas A toxin-mediated apoptosis. ADP ribosylation of elongation factor-2 is required for DNA fragmentation and cell lysis and synergy with tumor necrosis factor-alpha", J Immunol, 149, pp.2089~2094 (1992)
56. Murayama Y, "Cell-specific expression of the diphtheria toxin A-chain coding sequence under the control of the upstream region of the human alphafetoprotein gene", J Surg Oncol, 70, pp.145~149 (1999)
57. Ohana P, "Use of H19 regulatory sequences for targeted gene therapy in cancer", Int J Cancer, 98, pp.645~650 (2002)
58. Pachnis V, "The structure and expression of a novel gene activated in early mouse embryogenesis", EMBOJ, 7, pp.673~681 (1988)
59. Pagter-Holthuizen P, "Differential expression of the human insulin-like growth factor II gene. Characterization of the IGF-II mRNAs and an mRNA encoding a putative IGF-II-associated protein", Biophys Acta, 950, pp.282~295 (1988)
60. Pagter-Holthuizen P, "The human insulin-like growth factor II gene contains two development-specific promoters", FEBS Lett, 214, pp.259~264 (1987)
61. Paulus W, "Regulated expression of the diphtheria toxin A gene in human glioma cells using prokaryotic transcriptional control elements", J Neurosurg, 87, pp.89~95 (1997)
62. Pavelic K, "The role of insulinlike growth factor 2 and its receptors in human tumors", Mol Med, 8, pp.771~780 (2002)
63. Peng W, "Nano-particulate delivery of suicide DNA to murine prostate and prostate tumors", The Prostate, 67, pp.855~862 (2007)
64. Peng W, "Tightlyregulated suicide gene expression kills PSA-expressing prostate tumor cells", Gene Therapy, 12, pp.1573~1580 (2005)
65. Peng W, "Regulated expression of diphtheria toxin in prostate cancer cells", Mol Ther, 6, pp.537~545 (2002)
66. Poirier F, , Development, 113, pp.1105~1114 (1991)
67. Rachmilewitz J, "Parental imprinting of the human H19 gene", FEBS Lett, 309, pp.25~85 (1992)
68. Robert J, "Immunotoxins for target cancer therapy", The AAPS Journal, 8(3), pp.63~ (2006)
69. Robinson DF, "Suppression of single and double nonsense mutations introduced into the diphtheria toxin A-chain gene: a potential binary system for toxin gene therapy", Hum Gene Ther, 6, pp.137~143 (1995)
70. Rodriguez R, "Identification of diphtheria toxin via screening as a potent cell cycle and p53-independent cytotoxin for human prostate cancer therapeutics", Prostate, 34, pp.259~269 (1998)
71. Rolf JM, "Localization of the diphtheria toxin receptor-binding domain to the carboxylterminal Mr 6000 region of the toxin", J Biol Chem, 265, pp.7331~7337 (1990)
72. Rosen DG, "Potential markers that complement expression of CA125 in epithelial ovarian cancer", Gynecol Oncol, 99, pp.267~277 (2005)
73. Rothfels H, "Evaluation of combined gene regulatory elements for transcriptional targeting of suicide gene expression to malignant melanoma", Exp Dermatol, 12, pp.799~810 (2003)
74. Schenk-Braat EA, "Immunotherapy for superficial bladder cancer", Cancer Immunol Immunother, 54, pp.414~423 (2005)
75. Shapira A, "Toxin-based therapeutic approaches", Toxins, 2, pp.2519~2583 (2010)
76. Shi CX, "Superior tissuespecific expression from tyrosinase and prostate-specific antigen promoters", enhancers in helper-dependent compared with first-generation adenoviral vectors, 2002, pp.13, 211~224
77. Shirakawa T, "In vitro suppression of osteosarcoma pulmonary mestatasis with intravenous osteocalcin promoter-based toxic gene therapy", Cancer Gene Ther, 5, pp.274~280 (1998)
78. Showalter SL, "Nanoparticulate delivery of diphtheria toxin DNA effectively kills Mesothelin expressing pancreatic cancer cells", Canc Biol Ther, 7, pp.1584~1590 (2008)
79. Siegel R, "The impact of eliminating socioeconomic and racial disparities on premature cancer deaths", Cancer J Clin, 61, pp.212~236 (2011)
80. Smaldone MC, "BC-819, a plasmid comprising the H19 gene regulatory sequences and diphtheria toxin A, for the potential target therapy of cancers", Curr opin Mol Ther, 12(5), pp.607~616 (2010)
81. Smith TA, "Transient immunosuppression permits successful repetitive intravenous administration of an adenovirus vector", Gene Ther, 3, pp.496~502 (1996)
82. Sohda T, "Increased expression of insulin-like growth factor 2 in hepatocellular carcinoma is primarily regulated at the transcriptional level", Lab Invest, 75, pp.307~311 (1996)
83. Strauss N, "The effectof diphtheria toxin on the metabolism of HeLa cells", J Exp Medm, 109, pp.144~163 (1959)
84. Sutkowski DM, "Growth regulation of prostatic stromal cells by prostate-specific antigen", J Natl Cancer Inst, 91, pp.1663~1669 (1999)
85. Thomas CE, "Progress and problems with the use of viral vectors for gene therapy", Nature Reviews, 4, pp.346~358 (2004)
86. Thorburm A, "Induction of apoptosis by tumor cell- targeted toxins", Apoptosis, 9, pp.19~25 (2004)
87. Tsuneoka M, "Evidence for involvement of furin in cleavage and activation of diphtheria toxin", J Biol Chem, 268, pp.26461~26465 (1993)
88. Wang CY, "Recombinant baculovirus containing the diphtheria toxin a gene for malignant glioma therapy", Cancer Res, 66, pp.5798~5806 (2006)
89. Wilson BA, "Active-site mutations of diphtheria toxin. Tryptophan 50 is a major determinant of NAD affinity", J Biol Chem, 269, pp.23296~23301 (1994)
90. Yamaizumi M, "One molecule of diphtheria toxin fragment a introduced into a cell can kill the cell", Cell, 15, pp.245~250 (1978)
91. Ye X, "Transient depletion of CD4 lymphocyte improves efficacy of repeated administration of recombinant adenovirus in the ornithine transcarbamylase deficient sparse fur mouse", Gene Ther, 7, pp.1761~1767 (2000)
92. Zheng ZY, "Regression of prostate cancer xenografts by a lentiviral vector specifically expressing diphtheria toxin A", Cancer Gene Therapy, 10, pp.764~770 (2003)

관련 논문AI추천